VERSACROSS CONNECT FOR FARADRIVE
Report
- Report Number
- 2124215-2025-57520
- Event Type
- Injury
- Date Received
- August 18, 2025
- Date of Event
- July 29, 2025
- Report Date
- October 17, 2025
- Manufacturer
- BAYLIS MEDICALE CIE INC
- Product Code
- DXF
- PMA / PMN Number
- K150709
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- FR
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
THE DEVICE DID NOT RETURN FOR ANALYSIS. HOWEVER, THE REPORTED ALLEGATION RELATED TO THE HEMATOMA IS CONFIRMED THROUGH MEDIA, AND REMAINING REPORTED ALLEGATIONS ARE NOT CONFIRMED BASED ON THE MEDIA PROVIDED. IT WAS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION. IF THERE IS ANY FURTHER RELEVANT INFORMATION OBTAINED, A SUPPLEMENTAL MEDWATCH WILL BE FILED. THIS PRODUCT IS NOT APPROVED IN THE UNITED STATES; HOWEVER, IT HAS BEEN ASSESSED AS REPORTABLE AS THERE IS A SIMILAR PRODUCT APPROVED IN THE UNITED STATES. WE ARE UNABLE TO PROVIDE THE UNIQUE IDENTIFIER (UDI) # AND OTHER SPECIFIC PRODUCT INFORMATION RELATED TO UNITED STATES REGISTRATION AS THE SPECIFIC PRODUCT IS ONLY COMMERCIALLY AVAILABLE OUTSIDE OF THE UNITED STATES. GOOD FAITH EFFORT ATTEMPTS WERE MADE TO TRY AND RETRIEVE ADDITIONAL DETAILS REGARDING THE REPORTED EVENT, BUT FURTHER INFORMATION WAS UNABLE TO BE OBTAINED. CORRECTION TO THE INITIAL MDR IN BLOCK(S) PATIENT IDENTIFIER (A1), IN SECTION A - PATIENT INFORMATION.
IT WAS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION. IF THERE IS ANY FURTHER RELEVANT INFORMATION OBTAINED, A SUPPLEMENTAL MEDWATCH WILL BE FILED. THIS PRODUCT IS NOT APPROVED IN THE UNITED STATES; HOWEVER, IT HAS BEEN ASSESSED AS REPORTABLE AS THERE IS A SIMILAR PRODUCT APPROVED IN THE UNITED STATES. WE ARE UNABLE TO PROVIDE THE UNIQUE IDENTIFIER (UDI) # AND OTHER SPECIFIC PRODUCT INFORMATION RELATED TO UNITED STATES REGISTRATION AS THE SPECIFIC PRODUCT IS ONLY COMMERCIALLY AVAILABLE OUTSIDE OF THE UNITED STATES. GOOD FAITH EFFORT ATTEMPTS TO TRY AND RETRIEVE ADDITIONAL DETAILS REGARDING THE REPORTED EVENT ARE IN PROGRESS, BUT FURTHER INFORMATION WAS UNABLE TO BE OBTAINED YET. IF THERE IS ANY FURTHER RELEVANT INFORMATION OBTAINED, A SUPPLEMENTAL MEDWATCH WILL BE FILED.
IT WAS REPORTED THAT THE PATIENT EXPERIENCED EDEMA/INFLAMMATION/SWELLING AND HEMATOMA. THE PROCEDURE WAS CANCELLED. DURING A FARAVIEW PROCEDURE, A VERSACROSS CONNECT FOR FARADRIVE WAS SELECTED FOR USE. THE TRANSSEPTAL WAS BEING PERFORMED HOWEVER DUE TO A CONNECTION ERROR ON THE PHYSICIAN'S SIDE THE FIRST SHOT LEAD TO AN ERROR. THE PHYSICIAN THEN MADE TWO INCONCLUSIVE APPLICATIONS AND A THIRD ONE WHICH SEEMED TO PASS THE ETO IMAGE. A FOURTH APPLICATION WAS MADE SUSPECTING THE CONTACT ON THE PATIO AT THE LEVEL OF THE AORTA. IT WAS SUSPECTED THAT THE VERSACROSS APPLICATION WAS ON THE WALL FROM THE OG OPPOSITE THE AORTA. THUS, THE PROCEDURE WAS STOPPED FOLLOWING THE TRANSSEPTAL CHECK-UP. NO MEDICATION WAS PRESCRIBED, BUT A SCANNER. THE DEVICE IS NOT EXPECTED TO BE RETURNED FOR ANALYSIS (DISPOSED).
IT WAS REPORTED THAT THE PATIENT EXPERIENCED EDEMA/INFLAMMATION/SWELLING AND HEMATOMA. THE PROCEDURE WAS CANCELLED. DURING A FARAVIEW PROCEDURE, A VERSACROSS CONNECT FOR FARADRIVE WAS SELECTED FOR USE. THE TRANSSEPTAL WAS BEING PERFORMED HOWEVER DUE TO A CONNECTION ERROR ON THE PHYSICIAN'S SIDE THE FIRST SHOT LEAD TO AN ERROR. THE PHYSICIAN THEN MADE TWO INCONCLUSIVE APPLICATIONS AND A THIRD ONE WHICH SEEMED TO PASS THE ETO IMAGE. A FOURTH APPLICATION WAS MADE SUSPECTING THE CONTACT ON THE PATIO AT THE LEVEL OF THE AORTA. IT WAS SUSPECTED THAT THE VERSACROSS APPLICATION WAS ON THE WALL FROM THE OG OPPOSITE THE AORTA. THUS, THE PROCEDURE WAS STOPPED FOLLOWING THE TRANSSEPTAL CHECK-UP. NO MEDICATION WAS PRESCRIBED, BUT A SCANNER. THE DEVICE IS NOT EXPECTED TO BE RETURNED FOR ANALYSIS (DISPOSED).
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 2133666 | VERSACROSS CONNECT FOR FARADRIVE | CATHETER, SEPTOSTOMY | DXF | BAYLIS MEDICALE CIE INC | 0036584510 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 69 YR | Female | Required Intervention |